Wallace MC, Samuelson S, Khoo T, et al. - Researchers performed this single-centre, retrospective study to detect pretreatment variables that predict survival in hepatocellular carcinoma (HCC) patients treated with radioembolization (RE) to identify those who will benefit most from it and to inform the selection of patients for future trials. The sample consisted of consecutive individuals with HCC treated with RE from 2007 to 2018. One hundred thirteen patients with intermediate and advanced HCC followed for a median of 13.2 months were involved. Variables linked to superior survival used to derive the MAAPE score were lower Model for End-Stage Liver Disease score (< = 7), lower Alpha-fetoprotein (< = 150 IU/L), higher serum Albumin (> 37 g/L), absence of Portal vein tumour thrombus, and better performance status (ECOG = 0). Findings suggested that the MAAPE score correctly identifies patients with HCC for which RE is safe and effective. This will allow optimal selection of patients for future RE vs systemic therapy trials.